With President-elect Donald Trump’s (R) big victory and the GOP takeover of the U.S. Senate in last week’s elections, we [...] …
Articles by : Ted Slafsky, Publisher & CEO
After a long period in which many 340B providers felt helpless, the last month has brought two major wins. First, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Biden administration deserves credit for playing a key role in passing the first law in history to allow the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After six months of heated battles in the states to restore access to 340B drug discounts in the contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Pharmaceutical giant Eli Lilly has significantly escalated its restrictions on access to 340B pricing in the contract pharmacy setting, the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight. In fact, until the June [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
In last month’s column, I wrote about a reprehensible campaign by 340B opponents to tie this vital drug discount program [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After over 30 years of working in Washington, D.C., I have become accustomed to the expression “politics ain’t beanbag.” The [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
In February, the U.S. Senate bipartisan “Group of Six” released an eagerly anticipated discussion draft bill and a bill summary/request [...] …
